Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAM2904 + KAM3008 is a combination of two topical botanical formulations developed by Kamedis Ltd. for the management of mild to moderate atopic dermatitis (eczema) in children. KAM2904 is a face cream and KAM3008 is a body lotion, both of which are formulated with botanical extracts derived from Traditional Chinese Medicine (TCM) intended to restore the skin barrier and provide anti-inflammatory effects. The combination has been evaluated in clinical trials (such as NCT03810105) to assess its efficacy in reducing disease severity, as measured by SCORAD and Eczema Area Severity Index (EASI) scores, compared to standard petrolatum-based moisturizers. These products are often classified as medical devices or cosmeceuticals depending on the regulatory jurisdiction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KAM2904 + KAM3008.